SNDX Jan 2025 15.000 put
| Previous Close | 4.8000 |
| Open | N/A |
| Bid | 4.1000 |
| Ask | 7.0000 |
| Strike | 15.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 4.8000 - 4.8000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
PR NewswireSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 8, 2024.
PR NewswireSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.
PR NewswireSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Syndax Pharmaceuticals (NASDAQ: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) treated with revumenib, a first-in-class menin inhibitor. The pediatric data was featured in a Plenary Session titled "Pivotal Phase 2 R
